RAPA 501 ALLO
Alternative Names: Allogeneic hybrid TREG/Th2 Cells; RAPA-501-ALLOLatest Information Update: 28 Aug 2024
At a glance
- Originator Rapa Therapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Late-stage disease) in USA (IV, Infusion)
- 22 Jul 2020 Preclinical trials in COVID-2019 infections (Late-stage disease) in USA (IV) prior to July 2020
- 22 Jul 2020 Rapa Therapeutics plans a phase I/II trial for COVID-19 infections in USA (IV, Infusion) in September 2020 (NCT04482699)